McKesson Corporation Stock News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is how McKesson (MCK) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

A company capable of generating earnings well above its interest expense can withstand financial hardship. SFM, MOH, ATO and MCK are strong enough to meet financial obligations.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Warren Buffett is an investing legend because he's just that good. Since he became CEO of Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) in 1965, the Oracle of Omaha generated 3.7 million percent ret

While the glitz and glamour of the hottest technology firms organically command our attention, investors should earmark some time for researching value stocks to buy. Fundamentally, these under-the-ra

McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.

The Q2 earnings season is nearly in the books. As of Aug. 4, 84% of the S&P 500 had reported their results.

Dividend hikes reflect a company's commitment to returning value to shareholders, undoubtedly encouraging. And recently, all three of these companies have boosted their payouts.

Warren Buffett's Berkshire Hathaway Inc. took new stakes in home builders, bulked up on Capital One Financial Corp. and backed away from Activision Blizzard Inc. in the second quarter, according to qu

Warren Buffett's Berkshire Hathaway added a trio of homebuilders to its portfolio last quarter. The investor's company exited three stocks and slashed several of its positions, SEC filings show.

McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.

McKesson (MCK) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $5.83 per share a year ago.

Drug distributer McKesson on Wednesday raised its full-year profit forecast after strong demand for specialty medicines and weight-loss drugs helped the company beat estimates for first-quarter result

McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.